NCT04214860 2025-03-17APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesAprea TherapeuticsPhase 1 Completed51 enrolled 9 charts
NCT00900614 2019-07-31Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate CancerAprea TherapeuticsPhase 1 Completed36 enrolled